🚨 Real-World GLP-1 Data: Vanderbilt Obesity Clinic Study (n=2,306) Clinical trials showed 15–21% weight loss with semaglutide & tirzepatide. But how do patients actually fare in practice? - - - Key Findings: 📊 Median treatment duration: 10.7 months (50% discontinued by 12 months) 💉 Only 23% reached semaglutide 2.4 mg, 28% reached tirzepatide 15 mg ⚖️ Weight loss for those who continued treatment: • 6 months: –9.4% • 12 months: –14.4% 🏥 13.6% had medication-related ER visits (mostly GI side effects) Context: This was not a typical setting—patients had multidisciplinary support and NO-COST medication access through employer insurance bundles. Reality Check: ✅ With the right care model, real-world outcomes can approach RCTs ❌ Most patients never reach target doses ❌ Half stop treatment within a year 👉 The gap between “can work” and “does work” remains large. Sustained success appears tied to comprehensive care models that most patients can’t easily access. 🔗dom-pubs.pericles-prod.liter…